Serum levels of B-cell activating factor are associated with a reduced risk of chronic lymphocytic leukemia.
Authors
Frost E, Hofmann JN, Huang WY, Frazer-Abel AA, Deane KD, Berndt SI
Affiliations
- Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, USA.
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
- Department of Medicine, University of Colorado Anschutz Medical Campus, Denver, CO, USA.
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA. berndts@mail.nih.gov.
Abstract
Immune dysregulation is thought to contribute to chronic lymphocytic leukemia (CLL) risk, but biological mechanisms are unclear. We discovered that increased serum levels of B-cell activating factor (BAFF), an important regulator of B-cell maturation, were associated with a decreased risk of CLL, even >10 years after blood draw. Our findings suggest that BAFF could be a useful biomarker to assess risk among individuals at high risk, such as those with monoclonal b-cell lymphocytosis.
Publication Details
PubMed ID
39112445
Digital Object Identifier
10.1038/s41408-024-01106-7
Publication
Blood Cancer J. 2024 Aug 7; Volume 14 (Issue 1): Pages 132
- 2015-0051: Serum Levels of Autoantibodies and the Risk of Non-Hodgkin Lymphoma and Multiple Myeloma (Jonathan Hofmann - 2015 )